Most Cost-effective to Use Immunotherapy First in Melanoma Most Cost-effective to Use Immunotherapy First in Melanoma

Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news